Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

What is Tilray Inc.?

Tilray Brands Inc. (TLRY) is a prominent player in the global cannabis market, with a focus on the German market. The company is actively engaged in cost-saving strategies and acquisitions to drive its long-term growth goals.

Why is Tilray Inc. going down?

TLRY stock is down 5.3% on Apr 27, 2026 15:50

• Investors opted to take profits today amidst Tilray's stock decline, following a period of volatility and speculation.
• Concerns arose among investors due to a director's sale of over 33,000 company shares, potentially impacting outlook and causing fears of dilution.
• Although positive developments such as U.S. cannabis rescheduling and the company's expansion plans emerged, the stock's decline suggests some skepticism among investors regarding the recent surge.
• Tilray's larger-than-expected quarterly loss and negative net margins may have also influenced the stock's downturn, prompting an evaluation of the company's financial standing in light of sector trends.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Q3 2026 Tilray Brands Inc Earnings Call Transcript

Tilray Brands Inc. announced record third-quarter revenue of $206.7 million, an 11% year-over-year increase, driven by strong international cannabis growth, particularly in Germany. The company also completed Project 420, resulting in $33 million in annualized cost savings, and the acquisition of BrewDog positions it to become a $1.2 billion global revenue company. Despite a decline in the beverage segment's revenue and a net loss of $25.2 million, Tilray maintained a strong cash position and expects enhanced long-term growth.

https://www.gurufocus.com/stock/STU:2HQ0/transcripts/8765618

Tilray Brands (NASDAQ:TLRY) Shares Gap Up - Still a Buy?

Tilray Brands (NASDAQ:TLRY) shares significantly gapped up following positive news regarding U.S. cannabis rescheduling and statements from the company about its expansion plans. Despite this rally, driven by speculative interest and large call option buying, the article questions if it's a clear buying opportunity, pointing to the company's unprofitability, a consensus "Hold" analyst rating, and recent insider selling. The stock later pulled back after its initial surge, raising concerns about the rally's sustainability.

https://www.marketbeat.com/instant-alerts/tilray-brands-nasdaqtlry-shares-gap-up-still-a-buy-2026-04-23/

Tilray Brands (NASDAQ:TLRY) Stock Price Down 11.8% Following Insider Selling

Tilray Brands (NASDAQ:TLRY) shares dropped 11.8% after a director sold over 33,000 shares, leading to a significant increase in trading volume. The stock's performance reflects mixed analyst ratings, with some cutting price targets while others upgraded, alongside investor concerns about potential dilution despite sector optimism due to a possible Schedule III reclassification of cannabis. The company also reported a wider-than-expected quarterly loss and negative net margins.

https://www.marketbeat.com/instant-alerts/tilray-brands-nasdaqtlry-stock-price-down-118-following-insider-selling-2026-04-23/

Cannabis Stocks Rise and Fall on Rescheduling News; Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY) Rollercoaster Morning

Tilray Brands, Inc. experienced significant volatility in early trading following news of President Donald Trump's actions to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act. This move is seen as a pivotal moment for the U.S. cannabis industry, aligning federal policy with scientific and medical needs and opening up significant opportunities for medical cannabis research and patient access. Tilray's Chairman and CEO, Irwin D. Simon, applauded the decision, emphasizing the company's readiness to participate in expanding access to medical cannabis in the United States.

https://www.investorideas.com/news/2026/cannabis/04231-tilray-cannabis-rescheduling-volatility.asp

Tilray Surges 10%: Rescheduling Momentum Builds as Traders Await Official Confirmation

Tilray Brands (TLRY) shares surged 10% on Thursday, building on a 14% gain Wednesday, due to increasing speculation that the Trump administration will reclassify marijuana as a Schedule III drug. This potential regulatory change is expected to provide federal tax advantages and enable the expansion of Tilray's medical cannabis and pharma distribution platforms, as stated by CEO Irwin Simon. While the stock's rally is significant, the move remains speculative, with prediction markets showing cautious probabilities for rescheduling by year-end 2026, and investors are watching for official confirmation to sustain the bullish momentum.

https://247wallst.com/investing/2026/04/23/tilray-surges-10-rescheduling-momentum-builds-as-traders-await-official-confirmation/

Trending Today

Natural Gas ($GAS) Commodity Forecast: Up 8.2% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 5.2% Today

Chegg Inc. ($CHGG) Stock Forecast: Down 5.4% Today

Charter Communications Inc. ($CHTR) Stock Forecast: Down 5.0% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.1% Today

Flowserve Corporation ($FLS) Stock Forecast: Up 3.8% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 5.4% Today

Jetblue Airways Corporation ($JBLU) Stock Forecast: Down 5.3% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Down 6.1% Today

Tilray Inc. Price History

02.03.2026 - TLRY Stock was up 6.5%

• Strong Q3 earnings and a surge in international cannabis revenue contributed to Tilray exceeding revenue expectations, prompting a positive market response.
• Analysts raised their rating on Tilray to Buy, setting a price target of $10, and expressed optimism about the company's future growth potential.
• Despite the favorable earnings, concerns over varying margin trends, uncertainty in EPS reporting, and analyst downgrades caused a brief 5.1% decrease in the stock price after the earnings release, revealing the difficulties in maintaining consistent profitability amid revenue growth.

02.03.2026 - TLRY Stock was up 5.4%

• Despite achieving record Q3 revenue of $206.7 million, Tilray's stock declined by 5.1% due to concerns about mixed margin trends, confusion around EPS reporting, and analyst downgrades.
• The company's efforts in international cannabis revenue growth and strategic acquisitions were somewhat overshadowed by difficulties in converting top-line growth into consistent profit enhancements.
• Investors have reservations concerning a notable adjusted EPS shortfall, ongoing shareholder dilution, and slow advancements in U.S. cannabis rescheduling, which have influenced market perceptions despite the positive revenue outcome.
• Tilray's stock performance fell short of market expectations, closing well below its 52-week high, reflecting investor sentiment towards the company's financial performance and growth strategies.

27.03.2026 - TLRY Stock was down 5.3%

• Investors opted to take profits today amidst Tilray's stock decline, following a period of volatility and speculation.
• Concerns arose among investors due to a director's sale of over 33,000 company shares, potentially impacting outlook and causing fears of dilution.
• Although positive developments such as U.S. cannabis rescheduling and the company's expansion plans emerged, the stock's decline suggests some skepticism among investors regarding the recent surge.
• Tilray's larger-than-expected quarterly loss and negative net margins may have also influenced the stock's downturn, prompting an evaluation of the company's financial standing in light of sector trends.

07.03.2026 - TLRY Stock was down 5.1%

• Despite a positive day in the broader market, Tilray's stock faced a downward trend, closing at $6.66.
• Analysts hold differing views on Tilray, resulting in a consensus "Hold" rating and an average price target of $11.20. This reflects uncertainty regarding the company's future profitability.
• Investors have expressed concerns about Tilray's persistent operational losses, narrow margins, and high expenses, leading to a substantial 97% decline in the stock value over the past five years.
• The recent uptick in Tilray's stock price is possibly linked to short-term positive momentum driven by operational advancements in Q3. However, technical analysis indicates a consolidation range between $6.50 and $7.00, with potential downside risks due to the absence of strong buy signals.

01.03.2026 - TLRY Stock was down 5.1%

• Despite reporting record Q3 revenue of $206.7 million, Tilray's stock experienced a bearish movement due to concerns over a significant adjusted EPS miss, continuous shareholder dilution, and slow progress in U.S. cannabis rescheduling.
• The surge in international cannabis sales by 73% sparked a rally in Tilray's shares, but the narrowed net loss that still missed consensus might have contributed to the overall bearish sentiment.
• Anticipation of strong Q3 earnings, a new product launch, and decreased short interest led to a premarket surge in Tilray's stock, indicating short-term gains amidst a longer-term downtrend.
• Investors are eagerly waiting for revenue growth to translate into sustainable profitability for Tilray, as the company navigates through challenges and opportunities in the cannabis market.

22.03.2026 - TLRY Stock was up 14.6%

• The surge in Tilray Brands Inc. (TLRY) can be linked to the filing of additional legal exhibits related to a registration statement. This move likely boosted investor confidence in the company's adherence to regulations and transparency.
• Despite the notification of an insider selling 232,872 shares, the market appeared more interested in the registration of 398,666 resalable common shares, issued for acquiring the Lyphe Group. This development hinted at potential growth avenues for the company.
• The stock's positive trajectory might also reflect a recovery from the previous day's downturn, where it performed below the market average. Investors seem to perceive this as a favorable moment to purchase following the recent price dip.
• In summary, the optimistic market sentiment surrounding Tilray Brands Inc. could stem from its regulatory compliance, growth potential from acquisitions, and a rebound from the previous day's underperformance.

23.03.2026 - TLRY Stock was up 8.6%

• Tilray's stock price rose by more than 30% due to discussions about the possible reclassification of cannabis, which could support the company's plans for growth in the US market.
• There is excitement among investors regarding the potential regulatory changes that could lead to tax benefits and smoother operations for cannabis firms.
• Tilray's preparedness to tap into the US medical cannabis sector after a potential reclassification showcases strategic opportunities for growth and market expansion.
• By collaborating with BrewDog USA, Tilray is demonstrating a diverse approach to innovation and product offerings, which is contributing to its optimistic market sentiment and upward trajectory.

24.03.2026 - TLRY Stock was down 12.9%

• The stock price of Tilray Brands plummeted by 11.8% following insider selling of over 33,000 shares by a director, leading to increased trading volume and negative investor sentiment.
• Despite optimism in the cannabis sector due to potential reclassification of cannabis to Schedule III, concerns about potential dilution, wider-than-expected quarterly losses, and negative net margins contributed to the bearish movement.
• While there was speculation and anticipation surrounding the Trump administration's possible rescheduling of cannabis, the lack of official confirmation led to uncertainty and a sell-off in Tilray's stock.
• Tilray's readiness to expand into the U.S. medical cannabis market post-rescheduling highlights the company's strategic positioning, but until concrete regulatory changes are announced, the stock may continue to face volatility and downward pressure.

21.03.2026 - TLRY Stock was down 5.2%

• TLRY experienced a strong bearish movement today despite recent positive news and stock price gains in the past few days.
• The stock's poor performance could be attributed to the challenges faced in the legal marijuana market, including restrictive regulations on branding and advertising, intense competition, and uncertainty surrounding potential U.S. legalization.
• Despite reaffirming its leadership in medical cannabis and positive company news, the stock's reaction indicates a stock-specific response rather than a broader sector trend.
• The bearish movement today may be a result of profit-taking by investors following the recent price increases, as well as concerns about the company's ability to overcome regulatory hurdles and achieve sustained profitability in a competitive market.

14.03.2026 - TLRY Stock was up 8.5%

• The stock had a strong bullish movement today, closing 4.5% higher at $6.75.
• This positive momentum could be attributed to the recent launch of PORTAL™, a new high-intensity cannabis brand targeting experienced consumers in Canada, filling a market gap and potentially driving investor optimism.
• Despite facing legal challenges, such as the $11.3 million lawsuit from the Bob Marley estate over licensing royalties, Tilray's strategic product offerings and market expansion efforts seem to have resonated positively with investors, leading to today's bullish market movement.

13.03.2026 - TLRY Stock was up 5.2%

• Despite recent declines in the stock price and mixed trading sessions, today's bullish movement suggests a potential shift in investor sentiment.
• The launch of PORTAL™, a new high-intensity cannabis brand targeting experienced consumers, could have positively impacted the stock price as it signals the company's efforts to expand its product offerings and cater to specific market segments.
• The ongoing legal battle with the Bob Marley estate over licensing royalties might have initially caused uncertainty among investors, leading to the recent declines. However, the bullish movement today could indicate that investors are optimistic about a potential resolution or are focusing more on the company's product innovations.
• It's essential for investors to closely monitor any updates regarding the legal dispute and the company's financial performance to make informed decisions about their investments in Tilray Brands Inc.

31.02.2026 - TLRY Stock was up 5.3%

• The launch of Shock Top's "High Voltage" beer with bold orange flavors and a 9.6% ABV has created market buzz. However, investor focus appears to be more on the company's financial standing.
• Despite Tilray surpassing quarterly estimates, analysts have downgraded the stock to a "Hold" and reduced price targets, indicating concerns about profitability and financial well-being.
• The forthcoming earnings report on April 1st will be a key factor in shaping the stock's future direction, with investors eager to see if Tilray's financial performance shows any signs of recovery.
• Despite prevailing pessimism, the rise in institutional investors' holdings in the cannabis firm suggests enduring confidence in Tilray's growth prospects, potentially offering some stability to the stock in the short term.